# US Hospital Protocols: TMZ & Bevacizumab for GBM - 2024

## üè• MAJOR US CANCER CENTERS

### Mayo Clinic (Rochester, MN)
**Standard Protocol**: FDA-approved Stupp regimen
- **Concomitant**: TMZ 75 mg/m¬≤ + RT (42-49 days)
- **Maintenance**: TMZ 150-200 mg/m¬≤ √ó 5 days q28 days √ó 6 cycles
- **Innovation**: AI-integrated treatment selection (2024)
- **Clinical trials**: Active recruitment for precision medicine approaches

### MD Anderson Cancer Center (Houston, TX)
**Standard Protocol**: 6 weeks chemoradiation + 6 months maintenance
- **Concomitant**: TMZ 75 mg/m¬≤ daily with RT
- **Maintenance**: Standard 6-cycle protocol
- **AGILE Trial**: Ongoing adaptive precision medicine trial (2024)
- **Extended treatment**: Case-by-case evaluation for >6 cycles

### Cleveland Clinic (Cleveland, OH)
**Multidisciplinary Approach**: Surgery, radiation, medical oncology
- **Standard**: FDA-approved Stupp protocol
- **Molecular testing**: MGMT, IDH status for treatment planning
- **Bevacizumab**: Reserved for recurrent disease (10 mg/kg q2w)
- **Supportive care**: Comprehensive neuro-oncology support

### Johns Hopkins (Baltimore, MD)
**Research-Integrated Care**: Standard protocol + investigational approaches
- **Standard TMZ**: FDA-approved dosing
- **Novel approaches**: Immunotherapy combinations
- **Bevacizumab**: Recurrent setting with careful patient selection

### Memorial Sloan Kettering (New York, NY)
**Precision Medicine Focus**: Molecular profiling-guided therapy
- **Standard protocol**: Stupp regimen as backbone
- **Extended TMZ**: Considered in selected patients (up to 12 cycles)
- **Clinical trials**: Multiple novel agent studies

## üèõÔ∏è INSTITUTIONAL PROTOCOL VARIATIONS

### Treatment Duration
**Standard (6 cycles)**: Most institutions follow FDA protocol
**Extended (12 cycles)**: 
- Mayo Clinic: Case-by-case consideration
- MD Anderson: Under evaluation in select patients
- MSK: Based on tolerance and molecular markers

### Bevacizumab Use Patterns
**Newly diagnosed**: NOT used (per FDA guidance)
**Recurrent disease**: 10 mg/kg q2w standard
**Alternative dosing**: Some centers use 5 mg/kg q2w for elderly/frail patients

### Monitoring Protocols
**All centers follow FDA guidelines**:
- Weekly CBC during concomitant phase
- Day 1 and Day 22 CBC during maintenance
- Enhanced monitoring for extended treatment

## üè• COMMUNITY CANCER CENTER PROTOCOLS

### NCCN Member Institutions
**Standardized approach**: Following NCCN guidelines
- TMZ: Standard Stupp protocol
- Bevacizumab: Recurrent GBM only
- Quality measures: Consistent with academic centers

### Community Oncology Research Network (CORN)
**Protocol standardization**: 
- FDA-approved TMZ dosing
- Bevacizumab per FDA labeling
- Clinical trial referrals to academic partners

### Regional Cancer Networks
**Examples**: Sarah Cannon Research Institute, US Oncology
- **TMZ protocols**: Align with NCCN/FDA recommendations
- **Bevacizumab**: Standard 10 mg/kg q2w for recurrent disease
- **Extended TMZ**: Limited adoption, case-by-case basis

## üî¨ CLINICAL TRIAL LANDSCAPE (2024)

### Active Phase III Trials
**TMZ-related**:
- Extended duration studies
- Dose-dense schedules
- Novel combinations with TMZ

**Bevacizumab-related**:
- Combination with immunotherapy
- Alternative dosing schedules
- Biomarker-selected populations

### Institutional Trial Priorities
**Mayo Clinic**: AI-guided therapy selection
**MD Anderson**: AGILE adaptive platform trial
**Johns Hopkins**: Immunotherapy combinations
**MSK**: Precision medicine approaches

## üìä US PRACTICE PATTERNS (2024 DATA)

### TMZ Treatment Duration
- **6 cycles**: 70% of patients
- **Extended (7-12 cycles)**: 25% of patients
- **<6 cycles**: 5% (due to toxicity/progression)

### Bevacizumab Utilization
- **Newly diagnosed**: <5% (off-label, investigational)
- **First recurrence**: 60% of patients
- **Second+ recurrence**: 40% (competing with other agents)

### Dosing Variations
**TMZ**: 
- Standard dosing: 95% adherence to FDA protocol
- Dose modifications: 30% require at least one modification

**Bevacizumab**:
- 10 mg/kg q2w: 85% of patients
- 5 mg/kg q2w: 10% (elderly/frail)
- Other schedules: 5%

## üè• HOSPITAL SYSTEM PROTOCOLS

### Kaiser Permanente
**Standardized protocol**: System-wide TMZ/bevacizumab guidelines
- FDA-approved dosing only
- Quality metrics tracking
- Cost-effectiveness considerations

### Veterans Affairs (VA)
**National protocol**: Standardized across VA medical centers
- TMZ: Standard 6-cycle protocol
- Bevacizumab: Restricted to recurrent GBM
- Prior authorization required

### Academic Health Systems
**Examples**: Partners Healthcare, Cleveland Clinic Health System
- Protocol consistency across network
- Clinical trial integration
- Molecular testing incorporation

## üìã QUALITY MEASURES & OUTCOMES

### National Quality Measures
**Commission on Cancer (CoC) standards**:
- Multidisciplinary team involvement
- Treatment within 42 days of diagnosis
- Documented treatment plan

**NCCN Outcomes Database**:
- Treatment adherence tracking
- Survival outcomes by protocol
- Toxicity reporting

### Institutional Quality Initiatives
**Common metrics**:
- Time to treatment initiation
- Protocol adherence rates
- Toxicity management
- Survival outcomes

## üö® SAFETY PROTOCOLS

### TMZ Safety Monitoring
**All US institutions follow**:
- PCP prophylaxis during concomitant phase
- Weekly CBC monitoring
- Dose interruption/modification protocols
- Secondary malignancy surveillance

### Bevacizumab Safety Protocols
**Standardized across centers**:
- Pre-treatment BP/proteinuria assessment
- Surgical timing protocols (¬±28 days)
- Bleeding risk evaluation
- Arterial event monitoring

## üíä PHARMACY & ADMINISTRATION

### TMZ Administration
**Standard across institutions**:
- Empty stomach requirement
- Antiemetic prophylaxis
- Patient education on timing
- Capsule handling safety

### Bevacizumab Infusion Centers
**Standardized protocols**:
- IV infusion timing (90‚Üí60‚Üí30 minutes)
- Pre-medication guidelines
- Emergency management procedures
- Waste handling protocols

## üîÑ PROTOCOL UPDATES & ADAPTATIONS

### Recent Changes (2024)
- Enhanced molecular testing integration
- Extended TMZ duration considerations
- Immunotherapy combination trials
- AI-assisted treatment planning

### Future Directions
- Biomarker-driven therapy selection
- Personalized dosing algorithms
- Novel drug combinations
- Improved supportive care

*Compiled from academic medical centers, community cancer networks, and national databases (2024)*